市場調查報告書
商品編碼
1562240
2030 年亞太地區近視治療市場預測 - 區域分析 - 按類型、治療、年齡層和最終用戶Asia Pacific Myopia Treatment Market Forecast to 2030 - Regional Analysis - by Type, Treatment, Age Group, and End User |
2022年亞太近視治療市值為30.9716億美元,預計2030年將達63.4864億美元;預計2022年至2030年複合年成長率為9.4%。
用於治療目標近視的先進技術的不斷增加推動了亞太地區近視治療市場的發展
用於治療目標近視的先進技術的不斷增加對於近視治療市場來說是一個重大機會。雷射輔助原位角膜磨鑲術 (LASIK)、屈光性角膜切除術 (PRK) 和植入式人工水晶體 (ICL) 等技術的進步使得更有效地矯正近視成為可能,且併發症更少。大會期間也提出了各種突破性資料;由 Johnson & Johnson Vision 支援的 30 多篇摘要已獲批准展示。外科醫師可以應用創新的 SILK(即平滑切口透鏡狀角膜磨鑲術)治療來治療患有散光或不使用 ELITA™ 平台的近視患者。 ELITATM 平台憑藉其快速雷射傳輸技術和超精確雷射脈衝,為外科醫生提供了極其順利且簡單的晶狀體切除手術,並具有第二天的結果和康復效果。傳統上,這些先進技術價格昂貴,許多患者無法取得。儘管如此,隨著它們變得越來越廣泛,它們為近視治療市場提供了擴大其覆蓋範圍並為更多患者群體提供更好的治療選擇的機會。除了這些先進技術之外,其他新興治療方法,如角膜塑形術 (ortho-k) 和阿托品滴眼液,作為控制近視的有效方法也越來越受歡迎。這款廣受歡迎的角膜塑形鏡是獲得 CE 標誌的最新 CooperVision 近視控制產品,加入了 EyeDream 和 Paragon CRT 角膜塑形鏡設計、MiSight 日間軟性隱形眼鏡和 SightGlass 視覺擴散光學技術眼鏡鏡片。這些非侵入性治療比手術治療更便宜,使更多患者可以使用它們。總體而言,用於治療目標近視的先進技術的不斷增加為近視治療市場提供了重大機會。透過為患者提供更有效、更容易獲得的治療選擇,該市場可以幫助改善視力健康結果,並解決全球醫療保健領域未滿足的重大需求。
亞太近視治療市場概況
亞太近視治療市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。由於該地區人口老化加劇、研究數量不斷增加、政府支持力度加大以及眼部相關疾病增多,2022年該地區將佔亞太近視治療市場的30.14%以上。
在亞太地區,2022年,中國在亞太近視治療市場中佔據最大的市場佔有率。例如,根據人口資料局2020年發布的一項研究,到2050年,中國老年人口預計將達到約3.66億。 此外,根據同樣的估計,中國約26%的人口將超過到2050 年,這一數字將從2020 年的12% 上升到65 %。中國近視盛行率也大幅上升,尤其是兒童,可能會增加中國近視治療的採用。例如,根據《英國眼科雜誌》的數據,2019年中國學齡前兒童和中小學生近視盛行率為50.2%。此外,根據同一消息來源,2021年,6歲至16歲的兒童和青少年中有54.71%患有近視。
亞太地區近視治療市場收入及 2030 年預測(百萬美元)
亞太地區近視治療市場區隔
亞太地區近視治療市場按類型、治療、年齡層、最終用戶和國家分類。
根據類型,亞太近視治療市場分為高度近視、退化性近視和進行性近視。 2022 年,高度近視細分市場佔據亞太地區最大的近視治療市場。
在治療方面,亞太近視治療市場分為低劑量阿托品眼藥水、隱形眼鏡、角膜塑形鏡和屈光手術。 2022年,低劑量阿托品眼藥水細分市場佔據亞太地區最大的近視治療市場。
依年齡層別分類,亞太近視治療市場分為成人近視和兒童近視。 2022 年,成人近視細分市場將佔據亞太地區近視治療市場更大佔有率。
根據最終用戶,亞太近視治療市場分為醫院和診所、專科診所和屈光手術中心。 2022年,醫院和診所細分市場佔據亞太地區最大的近視治療市場。
依國家/地區分類,亞太地區近視治療市場分為澳洲、中國、日本、印度、韓國和亞太地區其他地區。 2022年,中國在亞太近視治療市場佔有率中佔據主導地位。
Bausch Health Companies Inc、Alcon AG、CooperVision Inc、Johnson & Johnson Vision Care Inc、Nidek Co Ltd、Haag-Streit AG 和 Carl Zeiss AG 是亞太近視治療市場上的一些領先公司。
The Asia Pacific myopia treatment market was valued at US$ 3,097.16 million in 2022 and is expected to reach US$ 6,348.64 million by 2030; it is estimated to register a CAGR of 9.4% from 2022 to 2030.
Rising Availability of Advanced Technologies for Treating the Targeted Myopia Boosts Asia Pacific Myopia Treatment Market
The rising availability of advanced technologies for treating targeted myopia is a significant opportunity for the myopia treatment market. Advances in technologies such as laser-assisted in-situ keratomileusis (LASIK), photorefractive keratectomy (PRK), and implantable collamer lenses (ICL) have made it possible to correct myopia more effectively and with fewer complications. Various ground-breaking data were also presented during the congress; over 30 abstracts backed by Johnson & Johnson Vision have been approved for presentation. Surgeons can apply the innovative SILK (i.e., Smooth Incision Lenticule Keratomileusis) treatment to treat myopic patients who have astigmatism or do not utilize the ELITATM Platform. The ELITATM Platform offers surgeons an exceptionally smooth and uncomplicated lenticular removal procedure with next-day outcomes and recovery owing to its fast laser delivery technology and ultra-precise laser pulse. These advanced technologies have traditionally been expensive and inaccessible to many patients. Still, as they become more widely available, they present an opportunity for the myopia treatment market to expand its reach and provide better treatment options to a larger patient population. In addition to these advanced technologies, other emerging treatments such as orthokeratology (ortho-k) and atropine eye drops are gaining popularity as effective methods for managing myopia. The popular orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Paragon CRT ortho-k designs, MiSight day soft contact lenses, and SightGlass Vision Diffusion Optics Technology spectacle lenses. These non-invasive treatments can be more affordable than surgical options, making them accessible to a wider range of patients. Overall, the rising availability of advanced technologies for treating targeted myopia presents a significant opportunity for the myopia treatment market. By providing patients with more effective and accessible treatment options, the market can help improve vision health outcomes and address a significant unmet need in the global healthcare landscape.
Asia Pacific Myopia Treatment Market Overview
Asia Pacific myopia treatment market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. This region accounted for over 30.14% of the Asia Pacific myopia treatment market in 2022 owing to the increasing aging population, rising number of research studies, growing government support, and increasing eye-related disorders in the region.
In Asia Pacific, China held the largest market share for Asia Pacific myopia treatment market in 2022. The market growth is primarily attributed to the aging population, the increasing prevalence of myopia, and the rising emphasis on preventive care. For instance, according to a study published by the Population Reference Bureau in 2020, the old-age population of China is expected to reach ~366 million by 2050. Moreover, according to the same estimates, around 26% of China's population will be over 65 by 2050, up from 12% in 2020. Such an extensively increasing geriatric population is anticipated to offer lucrative opportunities for the increased demand for products in the country. The country is also witnessing considerable growth in the prevalence of myopia, particularly in children, which is likely to increase the adoption of treatments in China. For instance, preschoolers and primary and secondary school students in China had a 50.2% prevalence of myopia in 2019, according to the British Journal of Ophthalmology. Additionally, according to the same source, 54.71% of children and adolescents between the ages of 6 and 16 had myopia overall in 2021. Thus, the increasing geriatric population and the increasing prevalence of myopia are driving the market growth.
Asia Pacific Myopia Treatment Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Myopia Treatment Market Segmentation
The Asia Pacific myopia treatment market is categorized into type, treatment, age group, end user, and country.
Based on type, the Asia Pacific myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest Asia Pacific myopia treatment market share in 2022.
In terms of treatment, the Asia Pacific myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest Asia Pacific myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.
By age group, the Asia Pacific myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger Asia Pacific myopia treatment market share in 2022.
Based on end user, the Asia Pacific myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest Asia Pacific myopia treatment market share in 2022.
Based on country, the Asia Pacific myopia treatment market is categorized into Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific myopia treatment market share in 2022.
Bausch Health Companies Inc, Alcon AG, CooperVision Inc, Johnson & Johnson Vision Care Inc, Nidek Co Ltd, Haag-Streit AG, and Carl Zeiss AG are some of the leading companies operating in the Asia Pacific myopia treatment market.